BiotechTube
Home/InSitu Biologics/Dan Halpern
DH

Dan Halpern

CEO

InSitu Biologics

Therapeutic Areas

Pain ManagementOncologyInfection

InSitu Biologics Pipeline

DrugIndicationPhase
INSB200™Peri-operative Pain ManagementPre-clinical
INSB400™Localized Cancer Drug DeliveryEarly Development

Leadership Team at InSitu Biologics

ME
Mark Ereth, MD
Chief Medical Officer
BT
Bill Taylor
Chief Science Officer
RW
Robert Wilson, MD
Board Chair
View full InSitu Biologics profile